BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 36220612)

  • 1. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice.
    Chen L; Qin Y; Guo T; Zhu W; Lin J; Xing T; Duan X; Zhang Y; Ruan E; Li X; Yin P; Li S; Li XJ; Yang S
    Cell Death Dis; 2024 May; 15(5):337. PubMed ID: 38744826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meso scale discovery-based assays for the detection of aggregated huntingtin.
    Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
    PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.
    Mende-Mueller LM; Toneff T; Hwang SR; Chesselet MF; Hook VY
    J Neurosci; 2001 Mar; 21(6):1830-7. PubMed ID: 11245667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
    Podvin S; Reardon HT; Yin K; Mosier C; Hook V
    J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper enhances aggregational toxicity of mutant huntingtin in a Drosophila model of Huntington's Disease.
    Lobato AG; Ortiz-Vega N; Zhu Y; Neupane D; Meier KK; Zhai RG
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166928. PubMed ID: 38660915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein changes in synaptosomes of Huntington's disease knock-in mice are dependent on age and brain region.
    Sapp E; Seeley C; Iuliano M; Weisman E; Vodicka P; DiFiglia M; Kegel-Gleason KB
    Neurobiol Dis; 2020 Jul; 141():104950. PubMed ID: 32439598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
    Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
    J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
    Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
    PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.
    Herrmann F; Hessmann M; Schaertl S; Berg-Rosseburg K; Brown CJ; Bursow G; Chiki A; Ebneth A; Gehrmann M; Hoeschen N; Hotze M; Jahn S; Johnson PD; Khetarpal V; Kiselyov A; Kottig K; Ladewig S; Lashuel H; Letschert S; Mills MR; Petersen K; Prime ME; Scheich C; Schmiedel G; Wityak J; Liu L; Dominguez C; Muñoz-Sanjuán I; Bard JA
    Sci Rep; 2021 Sep; 11(1):17977. PubMed ID: 34504195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic CAG Repeat Stability in a Transgenic Sheep Model of Huntington's Disease.
    Handley RR; Reid SJ; Burch Z; Jacobsen JC; Gillis T; Correia K; Rudiger SR; McLaughlin CJ; Bawden CS; MacDonald ME; Wheeler VC; Snell RG
    J Huntingtons Dis; 2024; 13(1):33-40. PubMed ID: 38393920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
    Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
    J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
    Kim YJ; Yi Y; Sapp E; Wang Y; Cuiffo B; Kegel KB; Qin ZH; Aronin N; DiFiglia M
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12784-9. PubMed ID: 11675509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.